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Abstract
Background: Osteoarthritis (OA) is the most common joint disorder in the USA, and knee OA has the highest
prevalence. Inflammation and decrease in vascularization are key factors in the degeneration of articular cartilage
and the associated pain and decrease in function. To combat this process, the use of biologics including umbilical
cord-derived Wharton’s Jelly (UC-derived WJ) has grown. UC-derived WJ contains large quantities of regenerative
factors, including growth factors (GFs), cytokines (CKs), hyaluronic acid (HA), and extracellular vesicles (EVs). The
proposed study evaluates the safety and efficacy of intraarticular injection of UC-derived WJ for treatment of knee
OA symptoms.
Methods and analysis: This is a non-randomized, open-label, multi-center, prospective study in which the safety
and efficacy of intraarticular UC-derived WJ in patients suffering from grade II/III OA will be assessed. Twelve
patients with grade II/III OA who meet the inclusion and exclusion criteria will be recruited for this study which will
be conducted at up to two sites within the USA. The participants will be followed for 1 s. Participants will be
assessed using the Numeric Pain Rating Scale (NPRS), Knee Injury and Osteoarthritis Outcome Score (KOOS), 36-item
short form survey (SF-36), Single Assessment Numeric Evaluation (SANE), physical exams, plain radiography, and
Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score for improvements in pain, satisfaction,
function, and cartilage regeneration.
Discussion: This prospective study will contribute to the limited amount of data on UC-derived WJ, particularly
with regard to its safety and efficacy. The outcomes from this study will also lay the groundwork for a large
placebo-controlled trial of intraarticular UC-derived WJ for symptomatic knee OA.
Trial registration: ClinicalTrials.gov NCT04719793. Registered on 22 January 2021
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Background
Osteoarthritis (OA) affects approximately 30 million
American adults aged 25–74 years, making it the most
common joint disorder in the USA [1]. OA is character-
ized by degeneration of articular cartilage and secondary
osteogenesis, with the earliest pathological changes seen
in the articular cartilage [2]. Larger weight-bearing joints
such as knees, hips, and the facet joints of the spine are
OA most frequent targets [3, 4]. Of all the joints it affects,
knee OA is the most prevalent with the number of adults
suffering expected to reach 67 million by 2030 [5, 6].
While knee OA is a prominent cause of disability in
adults, there is no clear etiology to explain its pathology.
Knee OA has been suggested to be related to age,
obesity, joint trauma, mechanical damage, gender, and
other factors [7, 8]. The pathology of knee OA may be
linked to degenerative lesions in cartilage secondary to
inflammation associated with hyperplasia and chondro-
cyte apoptosis [9, 10]. Increasing age is linked to a
reduction in subchondral blood vessels resulting in car-
tilage related physiological and biochemical anomalies
[11]. Additionally, the inability of long-chain hyaluronic
acid and polyglucose to generate chondrocytes results in
local softening of articular cartilage, loss of elasticity,
wear, and structural damage. This pathological process
results in secondary joint fibrosis, stiffness, pain, and de-
creased function; leading to a poor quality of life [8, 11].
Knee OA treatment aims to decrease or eradicate pain,
enhance or restore joint function, rectify any morpho-
logical or alignment defects, and improve quality of life.
Currently, there are various treatment options used in
clinical practice to manage knee OA, including activity
modification, physical therapy, pharmacological agents
such as NSAIDs, corticosteroids, viscosupplementation,
and narcotics. These treatment modalities have shown
variable and limited clinical benefits and have potential
side effects. When conservative measures fail, total knee
replacement is usually recommended [12–20]. While
total knee replacement (TKR) surgeries typically result
in decreased pain, improved joint function, and reduced
disability; complications, such as infection, persistent
pain, and loss of motion may occur, and may require re-
vision surgery. In addition, outcomes after TKR surgeries
for patients with less severe knee OA (grades II and III)
are worse compared to patients with grade IV OA (on
Kellgren-Lawrence scale) [21–23]. An additional goal of
non-operative therapy is to delay or even avoid surgical
intervention. Decreasing the number of TKR surgeries
will result in fewer revision surgeries, potentially saving
patients from multiple costly surgeries and extensive re-
habilitations, and decreasing the healthcare burden [21].
Over the last decade, the use of biologics for regenera-
tive medicine applications has gained popularity [24–30].
Despite their increased use, there are inadequate studies
evaluating the amount of growth factors (GFs), cytokines
(CKs), hyaluronic acid (HA), and extracellular vesicles
(EVs) including exosomes present in these products. Spe-
cifically, there is limited or no clinical literature assessing
the safety and efficacy of UC-derived WJ products. We
formulated an UC-derived WJ product and analyzed it for
the presence of these factors. The vital elements of regen-
erative medicine, namely GFs, CKs, HA, and EVs, are all
present in large quantities in the formulated WJ [31]. This
study allowed us to characterize this novel WJ formulation
prior to conducting clinical trials to determine the safety
and efficacy—for regenerative medicine applications.
The goal of the proposed study is to evaluate the safety
and efficacy of intraarticular injection of UC-derived WJ
for treatment of knee OA symptoms. We hypothesize
that the intraarticular injection of WJ is safe, and partici-
pants will show an improvement in their overall satisfac-
tion, Numeric Pain Rating Scale (NPRS), Knee Injury
and Osteoarthritis Outcome Score (KOOS), and cartil-
age formation over a period of 1 year compared to the
baseline visit. Our null hypothesis is that there is no
difference between baseline and after-treatment time-
points over a period of 1 year.
Methods and analysis
This study protocol is reported in accordance with the
Standard Protocol Items- Recommendations for Inter-
vention Trials (SPIRIT) criteria [31, 32]. The complete
SPIRIT checklist can be found in Supplementary data.
Study design
Twelve patients with grade II/III OA who meet the in-
clusion and exclusion criteria will be recruited for this
non-randomized, open label, multi-center, prospective
study. The study will be conducted at two sites within
the USA, and the patients will be followed for 1 year,
with an expected duration of 15 months (Figs. 1 and 2).
Figure 2 depicts the schedule for enrolment, intervention
and assessment according to the SPIRIT guidelines.
Inclusion criteria
Patients who are 18 years or older with a body mass
index (BMI) of < 40 kg/m2 and a diagnosis of mild to
moderate (grade II/III) OA in only one knee on the KL
grading scale will be recruited. Patients must also meet
the following criteria:
1. Pain score of 4 or more on the NPRS
2. Willing and capable of giving written informed
consent to participate
3. Willing and capable of complying with study-
related requirements, procedures, and visits
4. Female patients must be abstinent, surgically
sterilized, or postmenopausal
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Fig. 1 Summary of trial design
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5. Premenopausal females with negative pregnancy
test, and who does not anticipate pregnancy and
will actively practice an accepted contraceptive
method for a duration of the study
6. Males with premenopausal female partners will take
contraceptive measures for the duration of the
study
Exclusion criteria
Patients who have taken any pain medications including
non-steroidal anti-inflammatory drugs (except acet-
aminophen) within 15 days of the study injection date or
that regularly use anticoagulants, have a substance abuse
history and/or fail to agree not to take any knee-
symptom modifying drugs during the course of the study
without proper reporting to the site PI and study team
will not be eligible to participate. Patients must also not
meet the following criteria:
1. Evidence of pathological knee laxity or instability on
physical exam
2. History of intraarticular injection of any drug
including corticosteroids or viscosupplementation
in the index knee within the last 3 months
3. Knee surgery on the index knee within the last 6
months
4. Traumatic injury to the index knee within the last 3
months
5. Planned elective surgery during the course of the
study
6. Organ or hematologic transplantation history,
rheumatoid arthritis, or other autoimmune
disorders
7. Immunosuppressive medication/treatment
8. Diagnosis of non-basal cell carcinoma within the
last 5 years
9. A knee infection or use of antibiotics for a knee
infection within the last 3 months
10. Participation in another clinical trial or treatment
with any investigational product within the last 30
days prior to inclusion
11. Female patients who are breast feeding or are
pregnant or desire to be pregnant during the course
of the study
12. Contraindications to plain radiography or MRI
imaging
13. Serious neurological, psychological or psychiatric
disorders
14. Other medical conditions determined by the site
principal investigator as interfering with the study
15. An injury or disability claim under current litigation
or pending or approved workers’ compensation
claim
Participants will have the opportunity to voluntarily
withdraw from the study at any time without any
Fig. 2 Standard protocol items: recommendations for interventional trials (SPIRIT) flowchart
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sanction or affect to their access to other treatments.
The participation of a patient in the study may be termi-
nated if continued participation is not in the subject’s
best interest based on standard medical practice by the
PI. Any participant with any adverse events (AEs)
regardless of whether it is related to the treatment
can withdraw voluntarily from the study.
Study intervention
After patients are determined to be eligible for the study
during visit 1 (preliminary/baseline), they will receive an
intraarticular injection of UC-derived WJ (GeneXSTEMTM)
by the site PI during Visit 2.1 (procedure).
Assessment points
Assessments for the study period will start at visit 1
(preliminary/baseline) which includes a thorough review
of the patient’s inclusion/exclusion criteria and proper
documentation of the informed consent form prior to
participation. Once these steps are met, participant’s
demographic information, medical history, and baseline
case report forms (CRFs) such as NPRS, KOOS, 36-item
short-form survey (SF-36), and Single Assessment Nu-
meric Evaluation (SANE) will be collected. Baseline plain
radiography (Standing AP, Flexion PA (Rosenberg
method), Lateral, and Merchant views) for OA grading
using the KL scale will be obtained. Participants will also
undergo a T2-weighted MRI and receive a Magnetic
Resonance Observation of Cartilage Repair Tissue
(MOCART) score. Additionally, a comprehensive meta-
bolic profile, liver function tests, complete blood count,
markers of inflammation (C-reactive protein, erythrocyte
sedimentation rate), T,B and NK cell lymphocyte
subsets, and serum IgG, IgA, IgM, and IgE levels will be
collected. At visit 2.2, immediately after the injection
procedure, and at visits 3 (24-h follow-up) and 4 (48-h
follow-up), NPRS will be collected. During visits 5 (1-
week follow-up) and 6 (6-week follow-up), CRFs (NPRS,
KOOS, 7-point Likert scale, and SANE) will be collected.
Participants will also undergo a PE and have their
comprehensive metabolic profile, liver function tests,
complete blood count, markers of inflammation (C-re-
active protein, erythrocyte sedimentation rate), T,B and
NK cell lymphocyte subsets, and serum IgG, IgA, IgM,
and IgE levels collected. During visits 7 (3-month
follow-up) and 8 (6-month follow-up), participants will
undergo the same process as well as have plain radio-
graphs (standing AP, flexion PA (Rosenberg method),
lateral and merchant views) taken. During the partici-
pants’ final visit, visit 9 (1-year follow-up), the same
process as in visits 7 and 8 will be undertaken with an
additional T2-weighted MRI for a MOCART score.
Participants will have opportunities to report any AEs at
each visit or at any time during the study.
Endpoints
Primary endpoint
1. To determine the safety of intraarticular UC-derived
WJ formulation (GeneXSTEMTM).
Secondary endpoints
1. To assess change in patient-reported outcome
measures, NPRS and KOOS, from baseline to
various follow-up time points.
2. To assess cartilage formation via MOCART at the
1-year time point and compare if from baseline.
3. To assess patient satisfaction using SF-36, 7-point
Likert scale and Single Assessment Numeric
Evaluation (SANE).
Sample size and statistical analysis
Descriptive statistics will be computed for all study vari-
ables. Continuous variables will be described with mea-
sures of central tendency (mean, median) and dispersion
(range, standard deviation). Categorical variables will be
summarized as frequencies and percentages. Comparisons
between categorical variables will be compared with the
chi-square test; continuous variables will be compared
with Student’s t test or non-parametric equivalents. Paired
continuous data will be assessed with a paired t test or
Wilcoxon signed rank test, depending on distribution.
Paired categorical data will be assessed with McNemar’s
test. For the longitudinal data, a mixed-model repeated
measures analysis will be used to examine the between
subject factors and the within subject factor of time (base-
line, visit 1, visit 2, etc.), as well as their interaction, on the
outcome variables of interest. Post hoc tests with correc-
tions for multiple comparisons will be run to determine
where significance lies. P values < 0.05 will be considered
statically significant.
Data collection and handling
The PI will maintain all source documents. The data will
be duplicated on paper study CRFs, and the PI will
secure original data in order to be made available to the
sponsor and study monitors. Hard copies of CRFs and
media will be stored in a secure location and maintained
by the PI for a period of 7 years. CRFs will be available
for initial inspection for omitted data, data inconsisten-
cies, illegible data, and deviations by the study monitors.
The PI will be responsible for submitting data and
reports as follows:
a. AEs: in an ongoing basis. This will be reported in
the proper section of the CRF.
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b. Severe AEs: report within 24 h of knowledge of
event to sponsor and report to IRB within 5 days as
per their regulations.
c. Deviations, exceptions, violations of protocol: report
to sponsor within 5 days and report to IRB per
their regulations.
d. Protocol progress report: provide a copy to sponsor
and IRB as per regulations.
e. Study closure report: provide a copy to sponsor and
IRB as per regulations.
Quality control and assurance
Documents and data will be produced and maintained to
ensure control and protection of the patient’s privacy. The
protocol, CRFs, and medical records will be available for
access by the Sponsor, study monitors, and representatives
of regulatory authorities. All attempts will be made to
preserve the patient’s privacy and confidentiality.
Discussion
OA is the most common joint disorder in the USA. It
causes significant pain and loss of function for patients
and leads to significant strain on the healthcare system
[1]. The knee is the most commonly affected joint, and
current treatments of OA focus on decreasing pain,
increasing function, and improving quality of life. These
treatments, however, fail to effectively resolve the under-
lying pathophysiological processes involved in OA or
regenerate diseased cartilage. This is one of the many
reasons why the field of regenerative medicine and the
use of biologics including UC-derived WJ have grown so
rapidly.
This trial will be one the first to evaluate the safety
and efficacy of intraarticular UC-derived WJ with pa-
tients with grade II or III knee OA. We anticipate that
the intraarticular injection of UC-derived WJ is safe, and
participants will show an improvement in their overall
satisfaction, pain, function, and quality of life. We also
hypothesize that cartilage formation over a period of 1
year compared to the baseline visit will improve. Positive
outcomes from this study will also lay the foundation for
a large placebo-controlled trial of intraarticular UC-
derived WJ for symptomatic knee OA.
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